Get the Stockscreener App
0.387
7.50%
0.027
After Hours:
.38
-0.007
-1.81%
Organovo Holdings Inc stock is traded at $0.387, with a volume of 143.16K.
It is up +7.50% in the last 24 hours and up +4.88% over the past month.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
See More
Previous Close:
$0.36
Open:
$0.365
24h Volume:
143.16K
Relative Volume:
0.75
Market Cap:
$5.95M
Revenue:
-
Net Income/Loss:
$-19.09M
P/E Ratio:
-0.1783
EPS:
-2.17
Net Cash Flow:
$-16.92M
1W Performance:
-3.27%
1M Performance:
+4.88%
6M Performance:
-34.13%
1Y Performance:
-64.00%
1-Day Range:
$0.35
$0.39
1-Week Range:
$0.341
$0.4311
52-Week Range:
$0.3154
$1.74
Organovo Holdings Inc Stock (ONVO) Company Profile
Name
Organovo Holdings Inc
Sector
Industry
Phone
858-224-1000
Address
11555 SORRENTO VALLEY ROAD, SAN DIEGO, CA
Compare ONVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONVO
Organovo Holdings Inc
|
0.387 | 5.95M | 0 | -19.09M | -16.92M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Organovo Holdings Inc Stock (ONVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-18 | Initiated | H.C. Wainwright | Buy |
| Nov-10-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-25-17 | Initiated | Raymond James | Outperform |
| Aug-11-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Jun-29-15 | Initiated | Jefferies | Buy |
| Jun-29-15 | Initiated | Piper Jaffray | Overweight |
View All
Organovo Holdings Inc Stock (ONVO) Latest News
Organovo faces potential Nasdaq delisting - MSN
3D Bioprinting in Medical Market Worth $4.9 billion by 2032 | - openPR
Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com - Defense World
Organovo names new CFO amid clinical advancements By Investing.com - Investing.com Nigeria
Organovo Appoints Norman Staskey as Chief Financial Officer - citybiz
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer - The Manila Times
Organovo names new CFO amid clinical advancements - Investing.com
Organovo Appoints M&A Veteran CFO as FXR314 Drug Shows Promising Phase 2 Results - StockTitan
Organovo (NASDAQ:ONVO) Coverage Initiated at StockNews.com - Defense World
Organovo appoints new president and CFO amid strategic plans By Investing.com - Investing.com Nigeria
Organovo appoints new president and CFO amid strategic plans - Investing.com India
Organovo Holdings Appoints Norman Staskey as New CFO - TipRanks
Organovo (NASDAQ:ONVO) Now Covered by StockNews.com - Defense World
Analyzing Sorrento Therapeutics (OTCMKTS:SRNEQ) and Organovo (NASDAQ:ONVO) - Defense World
Healthcare 4D Printing Market Top Companies Study3D Systems - openPR
3D Print Organ Market 2024 to Witness Huge Growth by 2032 Prominent Players are Organovo Holdings, EnvisionTEC - openPR
3D Bioprinting for Tissue and Organ Regeneration Market Top - openPR
3D Bioprinting Equipment Sales Market Overview, Future Trends - openPR
3D-Printed Organs Market is experiencing new opportunities & competitive edge highlighted by Top Market Key Players (Organovo Holdings Inc., Modern Meadow, Poietis, REGEMAT 3D S.L., Cellbricks, Nano3D Biosciences, Inc.) | Forecast to 2030 - Industry Today
Empowering Growth: Bioprinting Services Market 2024 - openPR
3D Bioprinting Market is Forecast to Achieve USD 2.0 Billion - openPR
ONVO (Organovo Holdings) Enterprise Value : $5.31 Mil (As of Dec. 01, 2024) - GuruFocus.com
Organovo expands equity incentive plan following stockholder approval By Investing.com - Investing.com Nigeria
Organovo expands equity incentive plan following stockholder approval - Investing.com
Organovo Holdings Gains Approval for Key Strategic Moves - TipRanks
Industrial 3D Printing Market Size Analysis and Top Companies - Precedence Research
ONVOOrganovo Holdings Inc. Latest Stock News & Market Updates - StockTitan
Organovo reports positive Phase 2 results for liver drug FXR314 By Investing.com - Investing.com Australia
Organovo reports positive Phase 2 results for liver drug FXR314 - Investing.com India
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting - The Manila Times
Organovo's FXR314 Shows Significant Liver Fat Reduction in Phase 2 MASH Trial | ONVO Stock News - StockTitan
Human Liver Models Market 2024-2031| Emerging Technologies, - openPR
Organovo stock plunges to 52-week low of $0.35 amid market challenges - Investing.com India
3D Bioprinting Market Projected to Reach $$$ Billion by 2031 with - openPR
Armistice Capital, LLC Increases Stake in Organovo Holdings Inc - GuruFocus.com
Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight - GlobeNewswire Inc.
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases - The Manila Times
Organovo's FXR314 Drug Trial Data Selected for Major Liver Conference Presentation | ONVO Stock News - StockTitan
3D Printer Market to Grow by USD 30 Billion (2024-2028), Driven by Rising Consumer Demand for Customized Products, AI-Powered Report Highlights Market TransformationTechnavio - The Malaysian Reserve
Is Health Care's Hottest Stock a Mirage? - AOL
Organovo: Fiscal Q2 Earnings Snapshot - San Antonio Express-News
Organovo Holdings Inc (ONVO) Quarterly 10-Q Report - Quartzy
Organovo stock plunges to 52-week low of $0.39 amid market challenges - Investing.com Australia
Organovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.com - Defense World
Organovo stock plunges to 52-week low of $0.42 amid market challenges - Investing.com Canada
Organovo Holdings Inc Stock (ONVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):